Capio Biosciences

United States
Milford Square, Pennsylvania, United States, 53719

Company profile

Capio Biosciences company profile

Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.

Business identity

Contact email
[email protected]
Phone number
608) 441 8375
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2015-01-01, Year

Headquarters

Postal code
53719
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$2.9M
Last funding
Series A / $2.9M / 2017-01-05
Last equity funding
Series A / $2.9M
Investors
1
Lead investors
1
Founders
2
Articles
1

Founders and investors

Founders

Andrew WangSeungpyo Hong

Lead investors

Betta Pharmaceuticals

Investors

Betta Pharmaceuticals